Noxxon's NOX-E36 meets in diabetic nephropathy trial

Noxxon Pharma AG (Berlin, Germany) said twice-weekly subcutaneous NOX-E36 met the primary endpoint vs. placebo in a Phase IIa trial to treat diabetic nephropathy. NOX-E36 reduced urinary albumin excretion as measured by the change from baseline to week 12 in mean albumin-to-creatinine ratio (ACR) vs. placebo (30% vs. an increase of 2%, p=0.014). Additionally, 31% of patients receiving NOX-E36 achieved a 50% or greater reduction in mean ACR vs. 6% for placebo. The double-blind, international trial enrolled 75 Type II diabetics with albuminuria on current standard of care to control hypertension, hyperglycemia and dyslipidemia. Data were presented at the ISN Nexus Symposium in Bergamo. ...